Provided by Tiger Trade Technology Pte. Ltd.

Mistras Group Inc

20.75
+0.91004.59%
Post-market: 20.71-0.0411-0.20%19:56 EDT
Volume:2.56M
Turnover:53.32M
Market Cap:660.20M
PE:25.23
High:21.32
Open:20.66
Low:20.65
Close:19.84
52wk High:21.32
52wk Low:9.37
Shares:31.82M
Float Shares:9.51M
Volume Ratio:6.47
T/O Rate:26.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8225
EPS(LYR):0.5300
ROE:11.78%
ROA:6.35%
PB:2.75
PE(LYR):39.15

Loading ...

Mistras Group Inc: Oil and Gas Field Inspections May Continue to Be Impacted by High Crude Oil Prices Into Q2 of 2026

THOMSON REUTERS
·
May 06

Mistras Q1 Gross Profit USD 44.7 Million

THOMSON REUTERS
·
May 06

Mistras Group Inc - Reaffirms FY2026 Guidance

THOMSON REUTERS
·
May 06

Mistras Q1 Gross Margin 26.5%

THOMSON REUTERS
·
May 06

MISTRAS Announces First Quarter 2026 Results

GlobeNewswire
·
May 06

Mistras Group Inc expected to post earnings of 5 cents a share - Earnings Preview

Reuters
·
May 02

Roth Capital Partners Initiates Mistras at Buy With $22 Price Target

MT Newswires Live
·
Apr 30

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Apr 30

CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

GlobeNewswire
·
Apr 23

China Medical System’s MG‑K10 Allergy Drug NDA Accepted in China

TIPRANKS
·
Apr 23

CMS Announces NMPA Acceptance of New Drug Application for MG-K10 in Seasonal Allergic Rhinitis

Stock News
·
Apr 23

MISTRAS Group schedules quarterly results conference call

Reuters
·
Apr 22

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

GlobeNewswire
·
Apr 21

Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential

TIPRANKS
·
Apr 21

MISTRAS Group Receives Frost & Sullivan’s 2026 Global NDT Field Inspection Services Company of the Year Recognition

GlobeNewswire
·
Apr 20

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

GlobeNewswire
·
Apr 18

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

GlobeNewswire
·
Apr 09

MISTRAS Group announces annual shareholder meeting webcast

Reuters
·
Apr 08

MG Home Co Raises FY Net View to Y1.07B

Dow Jones
·
Apr 01